Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IONIS PHARMACEUTICALS INCIONS · Entity 1182 | EVP, Chief Development Officer | July 07, 2026 | July 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IONIS PHARMACEUTICALS INC
Report date July 07, 2026 · Filed July 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,096 |
Reported balance
After 2026-07-07 transaction · row 1
1 source rowRow 1 · 2026-07-07 · Sale · Disposed 362 · Balance 22,096 F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2026 |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2026
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 07, 2026 Filed Jul 9, 2026 22:07 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 362 | $84.30 | $30,516.60 |
DisclosureSEC source: 0000874015-26-000236 · edgardoc.xml · nonDerivative · entry 1 Kordasiewicz Holly B. · CIK 0002102721 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,096 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2026 Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 21:26 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $60.89 | $0.00 |
DisclosureSEC source: 0000874015-26-000208 · edgardoc.xml · derivative · entry 10 Kordasiewicz Holly B. · CIK 0002102721 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,000 shares Expires 2027-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 21:26 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 7,951 | $0.00 Strike: $60.89 | $0.00 |
DisclosureSEC source: 0000874015-26-000208 · edgardoc.xml · derivative · entry 9 Kordasiewicz Holly B. · CIK 0002102721 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 7,951 shares Expires 2027-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 21:26 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 19,895 | $0.00 Strike: $56.78 | $0.00 |
DisclosureSEC source: 0000874015-26-000208 · edgardoc.xml · derivative · entry 8 Kordasiewicz Holly B. · CIK 0002102721 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,895 shares Expires 2028-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 21:26 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $32.60 | $0.00 |
DisclosureSEC source: 0000874015-26-000208 · edgardoc.xml · derivative · entry 7 Kordasiewicz Holly B. · CIK 0002102721 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2032-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 21:26 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 19,842 | $74.05 | $1,469,306.05 |
DisclosureSEC source: 0000874015-26-000208 · edgardoc.xml · nonDerivative · entry 6 Kordasiewicz Holly B. · CIK 0002102721 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,458 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2026 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.735 to $74.28 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 21:26 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 41,004 | $73.09 | $2,997,121.77 |
DisclosureSEC source: 0000874015-26-000208 · edgardoc.xml · nonDerivative · entry 5 Kordasiewicz Holly B. · CIK 0002102721 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,300 F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2026 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.68 to $73.67 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 21:26 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 19,895 | $56.78 | $1,129,638.10 |
DisclosureSEC source: 0000874015-26-000208 · edgardoc.xml · nonDerivative · entry 4 Kordasiewicz Holly B. · CIK 0002102721 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,304 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 21:26 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 12,000 | $32.60 | $391,200.00 |
DisclosureSEC source: 0000874015-26-000208 · edgardoc.xml · nonDerivative · entry 3 Kordasiewicz Holly B. · CIK 0002102721 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 21:26 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 21,000 | $60.89 | $1,278,690.00 |
DisclosureSEC source: 0000874015-26-000208 · edgardoc.xml · nonDerivative · entry 2 Kordasiewicz Holly B. · CIK 0002102721 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 21:26 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 7,951 | $60.89 | $484,136.39 |
DisclosureSEC source: 0000874015-26-000208 · edgardoc.xml · nonDerivative · entry 1 Kordasiewicz Holly B. · CIK 0002102721 · EVP, Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 01:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | SaleCommon Stock | 4,141 | $75.66 | $313,308.06 |
DisclosureSEC source: 0000874015-26-000067 · edgardoc.xml · nonDerivative · entry 2 Kordasiewicz Holly B. · CIK 0002102721 · EVP, Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,718 F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.63 to $75.72 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Read SEC document |
| January 15, 2026 Filed Jan 21, 2026 01:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Unit · Derivative | 11,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-26-000067 · edgardoc.xml · derivative · entry 5 Kordasiewicz Holly B. · CIK 0002102721 · EVP, Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,730 Underlying: Common Stock · 11,250 shares Expires not disclosed F6 · security: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2026 Filed Jan 21, 2026 01:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantRestricted Stock Unit · Derivative | 13,650 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-26-000067 · edgardoc.xml · derivative · entry 4 Kordasiewicz Holly B. · CIK 0002102721 · EVP, Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,480 Underlying: Common Stock · 13,650 shares Expires not disclosed F6 · security: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2026 Filed Jan 21, 2026 01:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionRestricted Stock Unit · Derivative | 11,119 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000874015-26-000067 · edgardoc.xml · derivative · entry 3 Kordasiewicz Holly B. · CIK 0002102721 · EVP, Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,830 Underlying: Common Stock · 11,119 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2026 Filed Jan 21, 2026 01:18 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | Exercise / conversionCommon Stock | 11,119 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-26-000067 · edgardoc.xml · nonDerivative · entry 1 Kordasiewicz Holly B. · CIK 0002102721 · EVP, Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:34 UTC | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 9,100 | $0.00 Strike: $79.67 | $0.00 |
DisclosureSEC source: 0000874015-26-000022 · edgardoc.xml · derivative · entry 1 Kordasiewicz Holly B. · CIK 0002102721 · EVP, Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,100 Underlying: Common Stock · 9,100 shares Expires 2036-01-01 F1 · derivative.exercise_date: Grant on 01/02/2026 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2026. 25% of the shares subject to the option will vest and become exercisable on 01/02/2027. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years. Read SEC document |
| January 02, 2026 Filed Jan 21, 2026 01:20 UTC Amendment | IONIS PHARMACEUTICALS INC IONS · Entity 1182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $79.67 | $0.00 |
DisclosureSEC source: 0000874015-26-000068 · edgardoc.xml · derivative · entry 1 Kordasiewicz Holly B. · CIK 0002102721 · EVP, Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,600 Underlying: Common Stock · 7,500 shares Expires 2036-01-01 F1 · derivative.exercise_date: Grant on 01/02/2026 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2026. 25% of the shares subject to the option will vest and become exercisable on 01/02/2027. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.